Research Blog

One of the most important roles FPWR serves is that of a ‘convener’, bringing together those with an interest in advancing the science of PWS, and the care of those living with PWS. On Oct 5-6, 2023, FPWR held its annual PWS Research Symposium – our largest yet. More than 160 scientists,...
Source: FPWR Blog | Published: November 11 2023 - 10:15 AM
We are pleased to announce the recipients of the second round of grants for 2023, totaling $1,000,000 in awards, as part of the Foundation for Prader-Willi Research's (FPWR) ongoing commitment to advancing research in Prader-Willi (PWS) and Schaaf-Yang (SYS) syndromes. These grants support critical...
Source: FPWR Blog | Published: November 11 2023 - 09:15 AM
Soleno Therapeutics recently shared data from their DESTINY PWS study, an international, placebo-controlled Phase 3 study of DCCR (Diazoxide Choline Controlled-Release) drug trial. To further establish the effects of DCCR administration on hyperphagia, a randomized withdrawal period was initiated...
Source: FPWR Blog | Published: October 10 2023 - 09:00 AM
It is well known that individuals with Prader-Willi syndrome (PWS) display muscle weakness, hypotonia, and decreased lean muscle mass. Those with PWS have a 25–40% decrease in muscle mass compared to non-affected individuals, and muscle strength is approximately 70% lower than that of those without...
Source: FPWR Blog | Published: September 9 2023 - 09:15 AM
Sugar glucose is the body’s primary source of energy. Maintaining a healthy level of glucose in blood (not too high or too low), so that it can be delivered to all the other tissues of the body, is regulated by the hormone insulin. Insulin is produced in one very small part of the pancreas called...
Source: FPWR Blog | Published: July 7 2023 - 09:00 AM
See More »